Share Price and Basic Stock Data
Last Updated: November 22, 2025, 11:26 am
| PEG Ratio | -1,136.77 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Evexia Lifecare Ltd operates within the Edible Oils & Solvent Extraction industry, with its stock currently priced at ₹1.71 and a market capitalization of ₹321 Cr. The company has demonstrated fluctuating revenue trends over recent quarters. Sales stood at ₹13.80 Cr in June 2022, peaked at ₹24.78 Cr in March 2023, and recorded a subsequent decline to ₹10.65 Cr in September 2023. This volatility may reflect operational challenges and market conditions. For the fiscal year ending March 2024, total sales were reported at ₹56.27 Cr, lower than the ₹69.55 Cr recorded in March 2023, indicating a potential downward trend in revenue generation. However, the trailing twelve months (TTM) figures suggest a recovery to ₹94.11 Cr, hinting at improved performance in subsequent periods. The company’s sales performance is crucial for its long-term viability, as consistent revenue generation is essential within the competitive edible oils market.
Profitability and Efficiency Metrics
Evexia Lifecare’s profitability has exhibited significant volatility, reflected in its operating profit margin (OPM), which fluctuated from -2.75% in June 2022 to a high of 12.38% in March 2024. However, the OPM stood at just 4.89% in the most recent quarter, indicating marginal profitability. The net profit for the fiscal year ending March 2024 was reported at ₹1.38 Cr, an improvement from ₹0.67 Cr in March 2023. The company’s interest coverage ratio (ICR) of 3.88x remains healthy, suggesting it can comfortably meet its interest obligations. Nevertheless, the return on equity (ROE) and return on capital employed (ROCE) are relatively low at 0.32% and 0.30%, respectively. This indicates that while the company is generating profits, its efficiency in utilizing equity and capital to generate returns is suboptimal, which may concern investors seeking higher returns.
Balance Sheet Strength and Financial Ratios
As of the latest reporting, Evexia Lifecare has not disclosed any figures for reserves or borrowings, which raises questions regarding its financial flexibility. The company’s current ratio is reported at 1.49, suggesting a stable liquidity position, while the quick ratio stands at 1.46, indicating a healthy ability to meet short-term liabilities. However, the total debt to equity ratio is 0.83x, which is higher compared to typical industry standards, suggesting a reliance on debt financing. The price-to-book value (P/BV) ratio is 1.07x, reflecting a slight premium over its book value, indicating that investors are willing to pay more for each unit of net assets. The enterprise value (EV) of ₹877.51 Cr, combined with an EV/net operating revenue of 7.94x, suggests that the market is valuing the company at a high multiple relative to its revenue, which may indicate growth expectations or potential overvaluation.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Evexia Lifecare reveals a diversified ownership structure, with public shareholders holding 96.07% of the company. Promoter holdings have declined from 10.59% in December 2022 to 3.49% by March 2025, raising concerns about insider confidence in the company’s prospects. Institutional ownership is minimal, with foreign institutional investors (FIIs) at 0.47% and domestic institutional investors (DIIs) at 0.09%. This lack of institutional backing may reflect caution among larger investors regarding the company’s performance and growth potential. The total number of shareholders has also seen fluctuations, standing at 1,48,685 as of March 2025, which indicates a stable retail investor base. However, the declining promoter stake could impact investor confidence moving forward as it may signal a lack of commitment from company insiders.
Outlook, Risks, and Final Insight
Evexia Lifecare’s outlook hinges on its ability to stabilize revenue and enhance operational efficiency amidst a competitive landscape. The recent uptick in trailing twelve-month sales to ₹94.11 Cr provides a glimmer of hope for recovery, but the company must address its profitability challenges, as evidenced by low OPM and ROE figures. Risks include high reliance on debt, as indicated by the total debt to equity ratio, and declining promoter confidence, which could deter potential investors. The company’s operational performance will be closely scrutinized in the coming quarters, as any further declines in sales or profitability could exacerbate its financial challenges. Conversely, if Evexia can leverage its market position to improve margins and attract institutional investors, it may pave the way for a stronger financial footing and renewed investor confidence.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Evexia Lifecare Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| IEL Ltd | 100 Cr. | 7.69 | 10.3/3.87 | 3.37 | 0.00 % | 2.51 % | 1.91 % | 1.00 | |
| Evexia Lifecare Ltd | 323 Cr. | 1.72 | 4.40/1.52 | 226 | 3.02 | 0.00 % | 0.30 % | 0.32 % | 1.00 |
| Diligent Industries Ltd | 68.9 Cr. | 2.89 | 5.12/1.45 | 26.8 | 2.79 | 0.00 % | 7.06 % | 6.09 % | 1.00 |
| CIAN Agro Industries & Infrastructure Ltd | 4,237 Cr. | 1,514 | 3,633/321 | 2,087 | 33.0 | 0.00 % | 8.54 % | 1.06 % | 10.0 |
| BCL Industries Ltd | 1,048 Cr. | 35.5 | 58.3/33.0 | 10.1 | 28.9 | 0.73 % | 13.2 % | 13.0 % | 1.00 |
| Industry Average | 10,018.40 Cr | 177.65 | 169.00 | 33.77 | 0.18% | 14.09% | 12.05% | 4.00 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 13.80 | 12.41 | 18.57 | 24.78 | 14.02 | 10.65 | 6.75 | 24.72 | 21.23 | 26.71 | 21.70 | 23.61 | 22.09 |
| Expenses | 14.18 | 11.86 | 18.02 | 24.92 | 13.83 | 12.01 | 6.76 | 21.66 | 20.93 | 25.62 | 21.53 | 22.29 | 21.01 |
| Operating Profit | -0.38 | 0.55 | 0.55 | -0.14 | 0.19 | -1.36 | -0.01 | 3.06 | 0.30 | 1.09 | 0.17 | 1.32 | 1.08 |
| OPM % | -2.75% | 4.43% | 2.96% | -0.56% | 1.36% | -12.77% | -0.15% | 12.38% | 1.41% | 4.08% | 0.78% | 5.59% | 4.89% |
| Other Income | 0.49 | 0.35 | 0.86 | 0.18 | 0.20 | -0.20 | 0.00 | 0.86 | 0.13 | 0.00 | 0.10 | 0.00 | 0.00 |
| Interest | 0.01 | 0.15 | -0.14 | 0.52 | 0.00 | 0.01 | -0.01 | 0.49 | 0.00 | 0.05 | 0.00 | 0.41 | 0.01 |
| Depreciation | 0.09 | 0.10 | 0.10 | 0.10 | 0.10 | 0.10 | 0.07 | 0.15 | 0.10 | 0.11 | 0.11 | 0.46 | 0.21 |
| Profit before tax | 0.01 | 0.65 | 1.45 | -0.58 | 0.29 | -1.67 | -0.07 | 3.28 | 0.33 | 0.93 | 0.16 | 0.45 | 0.86 |
| Tax % | 0.00% | 56.92% | 26.21% | 41.38% | 27.59% | 0.00% | -28.57% | 16.77% | 24.24% | 25.81% | 25.00% | 31.11% | 25.58% |
| Net Profit | 0.01 | 0.29 | 1.07 | -0.83 | 0.22 | -1.67 | -0.05 | 2.73 | 0.24 | 0.69 | 0.12 | 0.31 | 0.63 |
| EPS in Rs | 0.00 | 0.00 | 0.02 | -0.01 | 0.00 | -0.03 | -0.00 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Last Updated: August 19, 2025, 3:46 pm
Below is a detailed analysis of the quarterly data for Evexia Lifecare Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 22.09 Cr.. The value appears to be declining and may need further review. It has decreased from 23.61 Cr. (Mar 2025) to 22.09 Cr., marking a decrease of 1.52 Cr..
- For Expenses, as of Jun 2025, the value is 21.01 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 22.29 Cr. (Mar 2025) to 21.01 Cr., marking a decrease of 1.28 Cr..
- For Operating Profit, as of Jun 2025, the value is 1.08 Cr.. The value appears to be declining and may need further review. It has decreased from 1.32 Cr. (Mar 2025) to 1.08 Cr., marking a decrease of 0.24 Cr..
- For OPM %, as of Jun 2025, the value is 4.89%. The value appears to be declining and may need further review. It has decreased from 5.59% (Mar 2025) to 4.89%, marking a decrease of 0.70%.
- For Other Income, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Interest, as of Jun 2025, the value is 0.01 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.41 Cr. (Mar 2025) to 0.01 Cr., marking a decrease of 0.40 Cr..
- For Depreciation, as of Jun 2025, the value is 0.21 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.46 Cr. (Mar 2025) to 0.21 Cr., marking a decrease of 0.25 Cr..
- For Profit before tax, as of Jun 2025, the value is 0.86 Cr.. The value appears strong and on an upward trend. It has increased from 0.45 Cr. (Mar 2025) to 0.86 Cr., marking an increase of 0.41 Cr..
- For Tax %, as of Jun 2025, the value is 25.58%. The value appears to be improving (decreasing) as expected. It has decreased from 31.11% (Mar 2025) to 25.58%, marking a decrease of 5.53%.
- For Net Profit, as of Jun 2025, the value is 0.63 Cr.. The value appears strong and on an upward trend. It has increased from 0.31 Cr. (Mar 2025) to 0.63 Cr., marking an increase of 0.32 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.00. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:23 am
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.62 | 33.96 | 177.53 | 74.10 | 105.42 | 100.20 | 106.63 | 75.51 | 69.55 | 56.27 | 110.48 | 94.11 |
| Expenses | 0.67 | 34.07 | 176.26 | 74.45 | 106.31 | 106.51 | 178.81 | 73.10 | 68.97 | 54.31 | 106.40 | 90.45 |
| Operating Profit | -0.05 | -0.11 | 1.27 | -0.35 | -0.89 | -6.31 | -72.18 | 2.41 | 0.58 | 1.96 | 4.08 | 3.66 |
| OPM % | -8.06% | -0.32% | 0.72% | -0.47% | -0.84% | -6.30% | -67.69% | 3.19% | 0.83% | 3.48% | 3.69% | 3.89% |
| Other Income | 0.43 | 0.51 | 0.16 | 1.27 | 3.48 | 11.72 | 74.35 | 0.07 | 1.88 | 0.88 | 0.14 | 0.10 |
| Interest | 0.02 | 0.05 | 0.02 | 0.02 | 0.02 | 0.21 | 0.01 | 0.10 | 0.54 | 0.49 | 1.09 | 0.47 |
| Depreciation | 0.20 | 0.08 | 0.08 | 0.18 | 0.32 | 0.31 | 0.24 | 0.21 | 0.39 | 0.42 | 1.70 | 0.89 |
| Profit before tax | 0.16 | 0.27 | 1.33 | 0.72 | 2.25 | 4.89 | 1.92 | 2.17 | 1.53 | 1.93 | 1.43 | 2.40 |
| Tax % | 31.25% | 40.74% | 32.33% | 33.33% | 30.22% | 29.24% | 33.33% | 60.37% | 56.21% | 28.50% | 35.66% | |
| Net Profit | 0.11 | 0.16 | 0.90 | 0.48 | 1.57 | 3.47 | 1.28 | 0.86 | 0.67 | 1.38 | 0.93 | 1.75 |
| EPS in Rs | 0.00 | 0.00 | 0.01 | 0.01 | 0.03 | 0.06 | 0.02 | 0.01 | 0.01 | 0.02 | 0.00 | 0.00 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 45.45% | 462.50% | -46.67% | 227.08% | 121.02% | -63.11% | -32.81% | -22.09% | 105.97% | -32.61% |
| Change in YoY Net Profit Growth (%) | 0.00% | 417.05% | -509.17% | 273.75% | -106.06% | -184.13% | 30.30% | 10.72% | 128.06% | -138.58% |
Evexia Lifecare Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 10 years from 2015-2016 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 68% |
| 5 Years: | 2% |
| 3 Years: | 14% |
| TTM: | 49% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 24% |
| 5 Years: | -23% |
| 3 Years: | 3% |
| TTM: | 40% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | -32% |
| 3 Years: | 6% |
| 1 Year: | -36% |
| Return on Equity | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | 1% |
| 3 Years: | 1% |
| Last Year: | 0% |
Last Updated: September 5, 2025, 3:26 pm
No data available for the Balance Sheet data table.
Cash Flow
| Month | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
Financial Efficiency Indicators
| Month | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 983.15 | 237.10 | 286.42 | 173.58 | 197.42 | 248.76 | 156.37 | 73.28 | 164.47 | 282.43 | 306.95 |
| Inventory Days | 197.30 | 4.70 | 1.64 | 3.03 | 2.98 | 2.27 | 11.70 | 6.96 | 11.18 | 8.00 | 11.30 |
| Days Payable | 187.43 | 383.91 | 73.29 | 67.30 | 158.16 | 171.51 | 114.48 | 124.30 | 186.39 | 194.93 | 261.26 |
| Cash Conversion Cycle | 993.01 | -142.11 | 214.77 | 109.31 | 42.23 | 79.52 | 53.58 | -44.05 | -10.74 | 95.49 | 56.99 |
| Working Capital Days | -1,577.74 | 248.17 | 250.48 | 277.72 | 133.78 | 244.83 | 192.00 | 175.23 | 207.30 | 343.08 | 111.73 |
| ROCE % | 0.44% | 1.83% | 0.98% | 2.86% | 6.20% | 2.30% | 2.63% | 0.47% | 0.30% | 0.30% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 2.00 | 10.00 |
| Basic EPS (Rs.) | 0.01 | 0.02 | 0.01 | 0.03 | 0.21 |
| Diluted EPS (Rs.) | 0.01 | 0.02 | 0.01 | 0.03 | 0.21 |
| Cash EPS (Rs.) | 0.01 | 0.02 | 0.01 | 0.03 | 0.24 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 2.45 | 1.73 | 1.25 | 2.37 | 11.72 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 2.45 | 1.83 | 1.36 | 2.60 | 12.86 |
| Revenue From Operations / Share (Rs.) | 0.58 | 0.79 | 1.05 | 2.44 | 17.22 |
| PBDIT / Share (Rs.) | 0.02 | 0.04 | 0.03 | 0.08 | 0.35 |
| PBIT / Share (Rs.) | 0.01 | 0.03 | 0.03 | 0.07 | 0.31 |
| PBT / Share (Rs.) | 0.01 | 0.02 | 0.02 | 0.07 | 0.31 |
| Net Profit / Share (Rs.) | 0.00 | 0.01 | 0.01 | 0.02 | 0.20 |
| NP After MI And SOA / Share (Rs.) | 0.00 | 0.01 | 0.01 | 0.02 | 0.20 |
| PBDIT Margin (%) | 3.81 | 5.04 | 3.54 | 3.28 | 2.04 |
| PBIT Margin (%) | 2.28 | 4.30 | 2.97 | 3.01 | 1.81 |
| PBT Margin (%) | 1.30 | 3.42 | 2.19 | 2.88 | 1.80 |
| Net Profit Margin (%) | 0.84 | 2.44 | 0.95 | 1.14 | 1.20 |
| NP After MI And SOA Margin (%) | 0.84 | 2.44 | 0.95 | 1.14 | 1.20 |
| Return on Networth / Equity (%) | 0.20 | 1.12 | 0.79 | 1.17 | 1.76 |
| Return on Capital Employeed (%) | 0.30 | 0.28 | 0.25 | 2.36 | 2.12 |
| Return On Assets (%) | 0.10 | 0.15 | 0.07 | 0.67 | 0.89 |
| Long Term Debt / Equity (X) | 0.81 | 5.53 | 8.34 | 0.00 | 0.01 |
| Total Debt / Equity (X) | 0.83 | 5.61 | 8.45 | 0.07 | 0.10 |
| Asset Turnover Ratio (%) | 0.12 | 0.06 | 0.14 | 0.53 | 0.27 |
| Current Ratio (X) | 1.49 | 2.23 | 1.86 | 2.67 | 2.10 |
| Quick Ratio (X) | 1.46 | 2.21 | 1.82 | 2.63 | 2.04 |
| Inventory Turnover Ratio (X) | 0.03 | 0.70 | 0.62 | 0.41 | 2.17 |
| Interest Coverage Ratio (X) | 3.88 | 5.76 | 4.56 | 24.67 | 182.81 |
| Interest Coverage Ratio (Post Tax) (X) | 1.86 | 3.80 | 2.23 | 9.56 | 108.78 |
| Enterprise Value (Cr.) | 877.51 | 858.85 | 812.50 | 182.67 | 916.31 |
| EV / Net Operating Revenue (X) | 7.94 | 15.26 | 11.68 | 2.42 | 8.59 |
| EV / EBITDA (X) | 207.97 | 302.64 | 329.87 | 73.54 | 421.22 |
| MarketCap / Net Operating Revenue (X) | 4.43 | 3.08 | 1.56 | 2.36 | 8.52 |
| Price / BV (X) | 1.07 | 1.42 | 1.30 | 2.43 | 12.53 |
| Price / Net Operating Revenue (X) | 4.43 | 3.08 | 1.56 | 2.36 | 8.52 |
| EarningsYield | 0.00 | 0.01 | 0.01 | 0.00 | 0.00 |
After reviewing the key financial ratios for Evexia Lifecare Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. It has decreased from 0.02 (Mar 24) to 0.01, marking a decrease of 0.01.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. It has decreased from 0.02 (Mar 24) to 0.01, marking a decrease of 0.01.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.01. This value is below the healthy minimum of 3. It has decreased from 0.02 (Mar 24) to 0.01, marking a decrease of 0.01.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 2.45. It has increased from 1.73 (Mar 24) to 2.45, marking an increase of 0.72.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 2.45. It has increased from 1.83 (Mar 24) to 2.45, marking an increase of 0.62.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 0.58. It has decreased from 0.79 (Mar 24) to 0.58, marking a decrease of 0.21.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 0.02. This value is below the healthy minimum of 2. It has decreased from 0.04 (Mar 24) to 0.02, marking a decrease of 0.02.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.01. This value is within the healthy range. It has decreased from 0.03 (Mar 24) to 0.01, marking a decrease of 0.02.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.01. This value is within the healthy range. It has decreased from 0.02 (Mar 24) to 0.01, marking a decrease of 0.01.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 2. It has decreased from 0.01 (Mar 24) to 0.00, marking a decrease of 0.01.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 2. It has decreased from 0.01 (Mar 24) to 0.00, marking a decrease of 0.01.
- For PBDIT Margin (%), as of Mar 25, the value is 3.81. This value is below the healthy minimum of 10. It has decreased from 5.04 (Mar 24) to 3.81, marking a decrease of 1.23.
- For PBIT Margin (%), as of Mar 25, the value is 2.28. This value is below the healthy minimum of 10. It has decreased from 4.30 (Mar 24) to 2.28, marking a decrease of 2.02.
- For PBT Margin (%), as of Mar 25, the value is 1.30. This value is below the healthy minimum of 10. It has decreased from 3.42 (Mar 24) to 1.30, marking a decrease of 2.12.
- For Net Profit Margin (%), as of Mar 25, the value is 0.84. This value is below the healthy minimum of 5. It has decreased from 2.44 (Mar 24) to 0.84, marking a decrease of 1.60.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 0.84. This value is below the healthy minimum of 8. It has decreased from 2.44 (Mar 24) to 0.84, marking a decrease of 1.60.
- For Return on Networth / Equity (%), as of Mar 25, the value is 0.20. This value is below the healthy minimum of 15. It has decreased from 1.12 (Mar 24) to 0.20, marking a decrease of 0.92.
- For Return on Capital Employeed (%), as of Mar 25, the value is 0.30. This value is below the healthy minimum of 10. It has increased from 0.28 (Mar 24) to 0.30, marking an increase of 0.02.
- For Return On Assets (%), as of Mar 25, the value is 0.10. This value is below the healthy minimum of 5. It has decreased from 0.15 (Mar 24) to 0.10, marking a decrease of 0.05.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.81. This value is within the healthy range. It has decreased from 5.53 (Mar 24) to 0.81, marking a decrease of 4.72.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.83. This value is within the healthy range. It has decreased from 5.61 (Mar 24) to 0.83, marking a decrease of 4.78.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.12. It has increased from 0.06 (Mar 24) to 0.12, marking an increase of 0.06.
- For Current Ratio (X), as of Mar 25, the value is 1.49. This value is below the healthy minimum of 1.5. It has decreased from 2.23 (Mar 24) to 1.49, marking a decrease of 0.74.
- For Quick Ratio (X), as of Mar 25, the value is 1.46. This value is within the healthy range. It has decreased from 2.21 (Mar 24) to 1.46, marking a decrease of 0.75.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 0.03. This value is below the healthy minimum of 4. It has decreased from 0.70 (Mar 24) to 0.03, marking a decrease of 0.67.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 3.88. This value is within the healthy range. It has decreased from 5.76 (Mar 24) to 3.88, marking a decrease of 1.88.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.86. This value is below the healthy minimum of 3. It has decreased from 3.80 (Mar 24) to 1.86, marking a decrease of 1.94.
- For Enterprise Value (Cr.), as of Mar 25, the value is 877.51. It has increased from 858.85 (Mar 24) to 877.51, marking an increase of 18.66.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 7.94. This value exceeds the healthy maximum of 3. It has decreased from 15.26 (Mar 24) to 7.94, marking a decrease of 7.32.
- For EV / EBITDA (X), as of Mar 25, the value is 207.97. This value exceeds the healthy maximum of 15. It has decreased from 302.64 (Mar 24) to 207.97, marking a decrease of 94.67.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 4.43. This value exceeds the healthy maximum of 3. It has increased from 3.08 (Mar 24) to 4.43, marking an increase of 1.35.
- For Price / BV (X), as of Mar 25, the value is 1.07. This value is within the healthy range. It has decreased from 1.42 (Mar 24) to 1.07, marking a decrease of 0.35.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 4.43. This value exceeds the healthy maximum of 3. It has increased from 3.08 (Mar 24) to 4.43, marking an increase of 1.35.
- For EarningsYield, as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. It has decreased from 0.01 (Mar 24) to 0.00, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Unable to fetch valid data for stock valuation.Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Evexia Lifecare Ltd:
- Net Profit Margin: 0.84%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 0.3% (Industry Average ROCE: 14.09%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 0.2% (Industry Average ROE: 12.05%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.86
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.46
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 226 (Industry average Stock P/E: 169)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.83
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0.84%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Edible Oils & Solvent Extraction | Tundav Anjesar Road, Village Tundav, Ta. Savli, Vadodra Gujarat 391775 | info@evexialifecare.com http://www.evexialifecare.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Jayesh R Thakkar | Chairman & Managing Director |
| Mr. Hasmukh D Thakkar | Non Exe.Non Ind.Director |
| Ms. Payal Gajjar | Ind. Non-Executive Director |
| Mr. Mohammadraza Makrani | Ind. Non-Executive Director |
| Mr. Kartik B Mistry | Ind. Non-Executive Director |
| Mr. Parth Patel | Ind. Non-Executive Director |